Eszopiclone

Limits on what this shows

• Key negative/null findings: None reported within this study. No human mitochondrial-biomarker study (membrane potential, electron-transport-chain activity, biogenesis markers) for eszopiclone was located in this review; this source measured electrophysiology and apoptotic morphology, not direct mitochondrial function, so its placement here is a labeled, conservative inference rather than a direct measurement.
• At-risk subgroups: None established in human data. Theoretical relevance to patients with untreated obstructive sleep apnea is unproven in humans; separately, the label cautions eszopiclone in patients with compromised respiratory function generally - that caution reflects the drug's own sedative/respiratory-depressant pharmacology and is not part of this finding (Hard Rule 2).
• Counter-evidence on record: Single-laboratory animal model; no independent replication located; no eszopiclone human mitochondrial data exist either way.

Regulatory status

Not addressed in the FDA/DailyMed label; not characterized by the manufacturer as a mitochondrial or nutrient-related effect.

Population evidence

Tier B, drug-specific animal study. Fung et al., Sleep 2009 (Sources [5]): anesthetized guinea pigs given intravenous eszopiclone 3 mg/kg before and during 3 hours of recurrent experimental apnea, versus vehicle control. Hippocampal CA1 field excitatory postsynaptic potentials and apoptotic morphology were measured.

Mechanism

Named: apnea produced a persistent, excitotoxic increase in CA1 synaptic responsiveness and significant neuronal apoptosis in untreated animals; eszopiclone antagonized both, acting as a neuroprotective agent the authors describe as "independent of its hypnotic properties."

Counter-evidence held on record

This is animal, mechanistic-level evidence of a protective neurological effect during experimentally induced hypoxia, not evidence of nutrient depletion or repletion. No supplementation or dosing recommendation follows from a yellow-tier entry.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence (drug-specific or class-level, cohort-tested) supports even a yellow grade, and no circulating claim exists to rebut as white.

Channels tried

Original pass: PubMed search-listing pages (multiple phrasings: "eszopiclone oxidative stress," "eszopiclone AND (ATP OR mitochondri*)"); general WebSearch across multiple phrasings ("eszopiclone oxidative stress antioxidant," "zopiclone copper OR iron OR oxidative stress OR free radical," "sleep medication Lunesta zopiclone oxidative stress free radical claim") returning only generically unrelated oxidative-stress literature; Crossref API and Europe PMC REST API attempts returned repeated HTTP 429. This revision pass (2026-10-01): the PubMed query "eszopiclone oxidative stress" was re-run fresh and returned the same 2 results as before - a 2014 LC-UV stability/degradation study measuring chemical, not physiological, oxidative degradation of the tablet formulation (not usable for this category), and Chan TY 2014, "Zopiclone induced methemoglobinemia and hemolytic anemia" (PMID 24569128), a review of an oxidative hematologic mechanism for the parent compound. Three separate channels were tried this pass to open PMID 24569128: the Europe PMC REST API (HTTP 429), the PubMed abstract page directly (returned a reCAPTCHA challenge page, no article content), and the journal's own site, dustri.com (fetch failed on a redirect loop). None succeeded, so per this protocol's rule against citing a source not opened, it remains disclosed but unused. (The 2025 herbal-formula/mitochondrial-biogenesis rat study, PMID 41357936, was successfully opened this pass via OpenAlex's per-PMID lookup and the publishing journal's own site - see the ATP production entry above - but it reports no redox/antioxidant-capacity marker (ROS, MDA, SOD, GSH), so it was deliberately not used to support this category.) A fresh general WebSearch could not be run this pass because the session's WebSearch budget (200/200) was already exhausted. Companion B009 sleep-agent dossiers in this same batch were checked for class-level evidence: suvorexant and lemborexant are both independently ungraded for oxidative stress; ramelteon (a melatonin-receptor agonist) is graded yellow for oxidative stress on the strength of melatonin's own well-characterized antioxidant chemistry in injury models - a mechanism specific to melatonin-receptor agonism, not GABA-A agonism, so it is not carried forward here as class support. The one eszopiclone-specific animal source already graded in this dossier (Fung et al. 2009, Sources [5]) measured electrophysiology and apoptotic morphology, not a redox/antioxidant-capacity marker, so it remains excluded from this category (see Mitochondrial burden entry instead). Dual condition for ungraded remains met: no openable Tier B/C evidence, no circulating claim.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence, no circulating claim.

Channels tried

Original pass: PubMed search-listing page for "eszopiclone copper" returned a clean zero-result page ("No results were found," 0 records) - a genuine literature gap, not a blocked attempt. General WebSearch for "eszopiclone iron OR copper OR ferritin OR hemoglobin OR hematocrit" and "zopiclone copper OR iron" returned only unrelated general nutrition/toxicology pages. Crossref API attempt for "eszopiclone copper" returned HTTP 429. This revision pass (2026-10-01): the combined query "eszopiclone AND (copper OR iron)" was re-run fresh on PubMed and again returned an explicit, clean zero-result page ("No results were found," result count 0), confirming the gap is not an artifact of the earlier query phrasing. A parallel query for the parent compound, "zopiclone copper OR iron," could not be completed this pass - the WebFetch proxy returned HTTP 429 (rate-limited) on pubmed.ncbi.nlm.nih.gov mid-session. The three companion B009 sleep-agent dossiers in this same batch (suvorexant, lemborexant, ramelteon) were cross-checked: all three are also independently ungraded for Copper, with no class member carrying any copper evidence - a genuine gap across the whole sleep-agent group reviewed in this batch, not a drug-specific or tooling-driven omission. Dual condition for ungraded remains met.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence, no circulating claim.

Channels tried

Original pass: PubMed search-listing page for "eszopiclone AND iron" returned a clean zero-result page (result count 0) - a genuine literature gap. General WebSearch across the same phrasings as Copper above returned nothing relevant. Europe PMC REST API and Crossref API attempts both returned HTTP 429. This revision pass (2026-10-01): the combined query "eszopiclone AND (copper OR iron)" was re-run fresh on PubMed and again returned an explicit, clean zero-result page ("No results were found," result count 0). Companion dossiers were cross-checked: suvorexant's own Iron entry independently documents a clean PubMed zero-result for "suvorexant" and iron; lemborexant and ramelteon are both ungraded for Iron as well. No class member in this batch carries iron evidence, confirming a genuine group-wide literature gap rather than a tooling artifact specific to eszopiclone. Dual condition for ungraded remains met.

Limits on what this shows

• Key negative/null findings: Tomizawa et al. 2021 found no significant benzodiazepine-class diversity effect, directly in tension with the Aasmets preprint's broader signal - the two Tier B/C sources disagree with each other.
• At-risk subgroups: None established for eszopiclone or any Z-drug.
• Counter-evidence on record: Conflicting class-level findings (above); neither source's cohort included eszopiclone or any other Z-drug (zolpidem, zopiclone, zaleplon) specifically - this is a loose, explicitly labeled class signal, not a strict cohort-test pass under Hard Rule 6.

Regulatory status

Not addressed in the FDA/DailyMed label.

Population evidence

Tier C, class extrapolation. Aasmets et al. 2024 (medRxiv preprint, not yet peer-reviewed; Sources [12]), Estonian Biobank cohort, n=2,509: "psycholeptics" (a drug category including benzodiazepines) showed microbiome compositional effects described as "even broader... compared to several antibiotic classes," detectable years after use. Against this, Tomizawa et al. 2021 ( Int J Neuropsychopharmacol, Sources [11]), a naturalistic clinical cohort that specifically studied etizolam, loflazepate, clonazepam, diazepam, alprazolam, and lorazepam as its anxiolytic/benzodiazepine group, found no significant relationship between that group and gut microbial alpha-diversity, in contrast to antipsychotics, which did show a dose-dependent diversity reduction in the same cohort.

Mechanism

Named but mechanistically distant for eszopiclone specifically: proposed routes include direct effects of the benzodiazepine chemical structure and GABA-A-mediated gut-brain-axis signaling. Eszopiclone's cyclopyrrolone structure differs from the benzodiazepine ring system, so a structural mechanism would not obviously transfer; a receptor-mediated (GABA-A) mechanism is the more defensible bridge, and is explicitly flagged as uncertain here.

Counter-evidence held on record

No probiotic, prebiotic, or dietary-fiber recommendation follows from this entry. The evidence does not establish that eszopiclone itself disrupts the gut microbiome - it establishes only that a pharmacologically related drug class has conflicting findings, and a future revision should re-run this search once Z-drug-specific microbiome data exist.

Limits on what this shows

• Key negative/null findings: The label's healthy-volunteer study at 7 mg (2.5-fold the maximum recommended therapeutic dose) found no respiratory-depressant effect and reports no methemoglobin signal. No methemoglobinemia case at therapeutic eszopiclone dosing was located.
• At-risk subgroups: Intentional-overdose or massive-ingestion patients; concomitant serotonergic drugs (the case patient was on mirtazapine) can complicate standard methylene-blue treatment, as in the cited case.
• Counter-evidence on record: No case at therapeutic dosing; no eszopiclone-specific (as opposed to racemic zopiclone) case identified.

Regulatory status

Methemoglobinemia is not listed as an eszopiclone/Lunesta adverse reaction in the FDA/DailyMed label.

Population evidence

Tier B, case report, parent compound. See, Fong & Lim, Cureus 2024 (Sources [10]): 78-year-old female ingested zopiclone 225 mg (approximately 30 tablets of 7.5 mg; typical eszopiclone dosing is 1-3 mg). Methemoglobin 10.4% on presentation, declining to 8.9%, 6.0%, 1.6%, and <1.0% over four days with IV ascorbic acid 1.5 g four times daily for two days plus one unit of packed red blood cells; hemoglobin rose from 8.2 to 9.2 g/dL post-transfusion. Dyspnea and the pulse-oximetry/arterial-blood-gas "saturation gap" resolved with treatment. Additional zopiclone-overdose case reports of methemoglobinemia and hemolytic anemia were identified by title/PMID in this search (see Sources, access-blocked list) but could not be opened during this review and are not cited as evidentiary support.

Mechanism

Named: the authors propose that amine-bearing metabolites undergo CYP-mediated N-hydroxylation, oxidizing hemoglobin to methemoglobin. This is the same CYP3A4/2E1 oxidative metabolic pathway described in the Pharmacokinetic Basis above (see Overlap map).

Counter-evidence held on record

This is a toxicologic overdose finding, not a therapeutic-dose or nutrient-deficiency finding. Ascorbic acid appears here only as emergency medical treatment for diagnosed methemoglobinemia under clinical supervision, never as a preventive supplement recommendation for ordinary eszopiclone use.

Limits on what this shows

• Key negative/null findings: The PCPA-induced model group showed significantly lower hypothalamic ATP than untreated normal controls (P<0.05), establishing the deficit against which eszopiclone and the herbal decoction were both tested. The source states "treatment with eszopiclone or SNSZRD (high/medium/low doses) significantly increased these parameters (P<0.05)" without separating eszopiclone's own absolute value or fold-change from the control comparison. No arm showed eszopiclone having no effect, or a negative effect, on ATP.
• At-risk subgroups: None established in human data; this is a single animal study with no clinical correlate identified.
• Counter-evidence on record: Single-laboratory animal model, not independently replicated; the model is of induced insomnia being corrected, not of chronic eszopiclone exposure in an otherwise undisturbed animal, so the finding may reflect correction of an insomnia-driven ATP deficit through sleep restoration generally rather than a direct pharmacologic action of eszopiclone on mitochondrial ATP synthesis. No human eszopiclone ATP data exist either way.

Regulatory status

Not addressed in the FDA/DailyMed label; no ATP or energy-metabolism finding is listed.

Population evidence

Tier B, drug-specific animal study, located and opened in this revision pass. Li RT, Lan B, Xiao ZY, Shi Q, Chen X, Li F. "Sini-Suanzaoren decoction regulates mitochondrial biogenesis mediated by MT-SIRT1 in the treatment of insomnia rats." World J Psychiatry. 2025;15(12):108867. PMID 41357936. DOI 10.5498/wjp.v15.i12.108867 (Sources [17]). 72 male Sprague-Dawley rats, n=12 per group across 6 groups, PCPA-induced insomnia model. Eszopiclone 0.89 mg/kg by oral gavage for 7 consecutive days served as the positive-control comparator against three doses of the herbal decoction under study. Hypothalamic ATP was measured by ELISA.

Mechanism

Proposed broadly as MT-SIRT1-mediated mitochondrial biogenesis (SIRT1, PGC-1α, NRF1, TFAM, mtDNA), but the retrieved full text reports quantified values for these markers only for the herbal-decoction dose groups, not isolated for the eszopiclone arm. The mechanism behind eszopiclone's own ATP effect is therefore not demonstrated by this source, only inferred from the shared study design; this is disclosed as a genuine limitation rather than implied as confirmed.

Counter-evidence held on record

This is animal, disease-model evidence of ATP correction alongside sleep restoration in rats, not evidence that eszopiclone increases cellular energy production in humans. No supplementation or dosing recommendation follows from a yellow-tier entry.